8-K: Viracta Therapeutics to be Delisted from Nasdaq, Shares to Trade on OTC Pink Open Market

Viracta Therapeutics receives delisting notice from Nasdaq due to non-compliance with listing rules and expects its shares to trade on the OTC Pink Open Market.

Summary

• Viracta Therapeutics received a delisting notice from Nasdaq on January 31, 2025.
• Trading of the company's common stock will be suspended on February 4, 2025.
• The delisting is due to non-compliance with Nasdaq's minimum share price requirement of $1.00 and stockholders' equity falling below $2,500,000.
• Nasdaq is expected to file a Form 25 with the SEC.
• The company anticipates its common stock will begin trading on the OTC Pink Open Market under the symbol VIRX.
• Trading on the OTC Pink Open Market may result in a less liquid market and could further depress the trading price of the common stock.
• There is no assurance that the company's common stock will continue to trade on this market or that broker-dealers will continue to provide public quotes.

Sentiment

Score: 2

Explanation: The document indicates a negative event (delisting from Nasdaq) which is generally unfavorable for investors. The move to the OTC Pink Open Market suggests financial difficulties and reduced market liquidity.

Negatives

• Viracta Therapeutics received a delisting notice from Nasdaq.
• The company's common stock will be suspended from trading on Nasdaq.
• Trading on the OTC Pink Open Market may result in a less liquid market.
• The delisting could further depress the trading price of the common stock.

Risks

• The company's common stock may experience a less liquid market on the OTC Pink Open Market.
• The trading price of the common stock could be further depressed.
• There is no assurance that the company's common stock will continue to trade on the OTC Pink Open Market.
• There is no guarantee that broker-dealers will continue to provide public quotes of the company's common stock.
• The trading volume of the company's common stock may not be sufficient to provide for an efficient trading market.

Future Outlook

The company expects its common stock to begin trading on the OTC Pink Open Market under the symbol VIRX, but there are risks associated with trading on this market.

Industry Context

Delisting from major exchanges like Nasdaq can negatively impact a company's visibility, investor confidence, and access to capital. Companies facing delisting often seek to regain compliance or explore alternative listing options.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment.
• Shareholders may find it more difficult to trade the company's common stock.
• The company's ability to raise capital may be negatively impacted.

Next Steps

• Nasdaq is expected to file a Form 25 with the SEC.
• The company expects its common stock to begin trading on the OTC Pink Open Market.

Key Dates